BRPI0905847A2 - "composição farmacêutica injetável e processo para preparar a composição" - Google Patents
"composição farmacêutica injetável e processo para preparar a composição"Info
- Publication number
- BRPI0905847A2 BRPI0905847A2 BRPI0905847A BRPI0905847A BRPI0905847A2 BR PI0905847 A2 BRPI0905847 A2 BR PI0905847A2 BR PI0905847 A BRPI0905847 A BR PI0905847A BR PI0905847 A BRPI0905847 A BR PI0905847A BR PI0905847 A2 BRPI0905847 A2 BR PI0905847A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- preparing
- injectable pharmaceutical
- pharmaceutical composition
- injectable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2510708P | 2008-01-31 | 2008-01-31 | |
| FR0850617 | 2008-01-31 | ||
| US61/025,107 | 2008-01-31 | ||
| FR0850617A FR2926996B1 (fr) | 2008-01-31 | 2008-01-31 | Composition pharmaceutique a proprietes gelifiantes contenant un derive de tyrosine |
| PCT/EP2009/051085 WO2009095485A1 (en) | 2008-01-31 | 2009-01-30 | Pharmaceutical composition with gelling properties containing a tyrosine derivative |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0905847A2 true BRPI0905847A2 (pt) | 2016-08-09 |
| BRPI0905847B1 BRPI0905847B1 (pt) | 2019-05-14 |
| BRPI0905847B8 BRPI0905847B8 (pt) | 2021-05-25 |
Family
ID=39627409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0905847A BRPI0905847B8 (pt) | 2008-01-31 | 2009-01-30 | composição farmacêutica injetável |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8815944B2 (pt) |
| EP (1) | EP2254550B1 (pt) |
| JP (1) | JP5587211B2 (pt) |
| CN (1) | CN101969924B (pt) |
| AU (1) | AU2009209546B2 (pt) |
| BR (1) | BRPI0905847B8 (pt) |
| CA (1) | CA2713266C (pt) |
| ES (1) | ES2402468T3 (pt) |
| FR (1) | FR2926996B1 (pt) |
| WO (1) | WO2009095485A1 (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8852638B2 (en) | 2005-09-30 | 2014-10-07 | Durect Corporation | Sustained release small molecule drug formulation |
| BRPI0811319A2 (pt) | 2007-05-25 | 2015-02-10 | Tolmar Therapeutics Inc | Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| GB2513060B (en) | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| JP5616529B2 (ja) * | 2010-08-27 | 2014-10-29 | ネオファーム カンパニー， リミテッド | ヒト抗菌ペプチド分泌促進用組成物 |
| WO2012039768A2 (en) * | 2010-09-24 | 2012-03-29 | Texas Southern University | Itraconazole formulations |
| CN102432491B (zh) * | 2011-09-08 | 2013-10-23 | 西安科技大学 | 一种基于酪氨酸衍生物的胶凝剂及其应用 |
| CN103980148B (zh) * | 2014-01-08 | 2016-09-14 | 上海交通大学医学院 | 硬脂酰氨基酸盐及其制备方法和应用 |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| EP3454663A1 (en) * | 2016-05-12 | 2019-03-20 | Rudjer Boskovic Institute | Low molecular weight organic gelators of vegetable oil |
| WO2020125926A1 (en) | 2018-12-17 | 2020-06-25 | Rudjer Boskovic Institute | Composition comprising oxalamide gelators and vegetable oil |
| US11613889B2 (en) | 2019-10-04 | 2023-03-28 | Innovations & Ideas, Llc | Weeping control joint system |
| CN111545139B (zh) * | 2020-06-04 | 2022-03-11 | 云南中烟工业有限责任公司 | 含糖基-酰胺基-芳基-烃基四段式糖基胶凝剂的可逆相变雾化液凝胶及其制备方法和应用 |
| CN113563219B (zh) * | 2021-07-29 | 2023-12-26 | 沈阳药科大学 | L-酪氨酸衍生物和球状介孔二氧化硅纳米粒及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3969087A (en) | 1974-08-07 | 1976-07-13 | Ajinomoto Co., Ltd. | Gels of nonpolar liquids with N-acyl amino acids and derivatives thereof as gelling agents |
| BE1011899A6 (fr) | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
| US7691408B2 (en) * | 2002-03-12 | 2010-04-06 | Ethypharm | Composition having gelling properties for the prolonged delivery of bioactive substances |
| US20050031650A1 (en) | 2002-08-26 | 2005-02-10 | Ethypharm | Composition with gelling properties for the sustained delivery of bioactive substances |
| CN101431983A (zh) * | 2004-09-28 | 2009-05-13 | 香港科技大学 | 作为生物材料的多功能的超分子水凝胶 |
| CN1868543A (zh) * | 2006-06-20 | 2006-11-29 | 四川大学 | 一种生物降解高分子凝胶药物组合物及其制备方法和用途 |
| CN101007170A (zh) * | 2007-01-25 | 2007-08-01 | 上海交通大学 | 包虫病药物缓释制剂的制备方法 |
-
2008
- 2008-01-31 FR FR0850617A patent/FR2926996B1/fr active Active
-
2009
- 2009-01-30 WO PCT/EP2009/051085 patent/WO2009095485A1/en active Application Filing
- 2009-01-30 CA CA2713266A patent/CA2713266C/en active Active
- 2009-01-30 BR BRPI0905847A patent/BRPI0905847B8/pt active IP Right Grant
- 2009-01-30 JP JP2010544720A patent/JP5587211B2/ja active Active
- 2009-01-30 EP EP09705063A patent/EP2254550B1/en active Active
- 2009-01-30 US US12/864,909 patent/US8815944B2/en active Active
- 2009-01-30 CN CN2009801034996A patent/CN101969924B/zh active Active
- 2009-01-30 ES ES09705063T patent/ES2402468T3/es active Active
- 2009-01-30 AU AU2009209546A patent/AU2009209546B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2713266C (en) | 2016-02-16 |
| US8815944B2 (en) | 2014-08-26 |
| US20110207813A1 (en) | 2011-08-25 |
| JP2011510955A (ja) | 2011-04-07 |
| EP2254550B1 (en) | 2013-01-09 |
| FR2926996B1 (fr) | 2013-06-21 |
| JP5587211B2 (ja) | 2014-09-10 |
| AU2009209546A1 (en) | 2009-08-06 |
| FR2926996A1 (fr) | 2009-08-07 |
| CN101969924B (zh) | 2012-10-24 |
| BRPI0905847B8 (pt) | 2021-05-25 |
| AU2009209546B2 (en) | 2013-12-19 |
| WO2009095485A1 (en) | 2009-08-06 |
| BRPI0905847B1 (pt) | 2019-05-14 |
| CN101969924A (zh) | 2011-02-09 |
| EP2254550A1 (en) | 2010-12-01 |
| ES2402468T3 (es) | 2013-05-06 |
| CA2713266A1 (en) | 2009-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0905847A2 (pt) | "composição farmacêutica injetável e processo para preparar a composição" | |
| BRPI0905717A2 (pt) | Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica | |
| LTPA2018014I1 (lt) | Farmacinė kompozicija 514 | |
| BRPI0818533A2 (pt) | composto, composição farmacêutica, e, processo para a preparação de um composto | |
| BRPI0814611A2 (pt) | Composição, processo para preparar uma composição, e, uso de uma composição | |
| BRPI0821676A2 (pt) | Composto, composição farmacêutica, e, processo para a preparação dos compostos. | |
| BRPI0816807A2 (pt) | bortezomib e processo para a produção do mesmo | |
| BRPI0813611A2 (pt) | "composição, polímero, processo para preparar um polímero e artigo" | |
| BRPI0813307A2 (pt) | Composição imunogênica, vacina, e, processo para fabricar a vacina | |
| BRPI0816513A2 (pt) | Composição farmacêutica e método para preparar a suspensão sólida | |
| BRPI0807807A2 (pt) | " composição farmacêutica de liberação modificada e um processo para fabricar a mesma ". | |
| BRPI0816553A2 (pt) | "composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto" | |
| BRPI1008127A2 (pt) | "composição e processo para a preparação de uma espuma termoplástica ou termofixa" | |
| BRPI0812064A2 (pt) | Formulação farmacêutica, tabletes, e, processo para a produção de uma formulação farmacêutica | |
| BRPI0814153A2 (pt) | "método para preparar um composto e composto" | |
| BRPI0812647A2 (pt) | "composição e método para produzir a composição" | |
| BRPI0812703A2 (pt) | "processo para preparar um material de barreira de gás e embalagem preparada com tal material" | |
| BRPI0914083A2 (pt) | "painél compósito e processo para fabricar um painél compósito" | |
| BRPI1015061A2 (pt) | "processo para a preparação contínua de isocianatos" | |
| BRPI0814821A2 (pt) | Composto, composição farmacêutica, e, processo para preparar um composto | |
| BRPI0910545A2 (pt) | processo contínuo para fazer composições farmacêuticas | |
| BRPI0720530A2 (pt) | Partícula, processo para preparar a partícular, e, composição | |
| BRPI1007161A2 (pt) | composição farmacêutica oral, e processo para preparar uma composição | |
| BRPI0915365A2 (pt) | Processo para a preparação de 2-triflúor-metil-5-alquil-piridinas substituídas na posição 1 | |
| BR112012016201A2 (pt) | ''composto, processo para a preparação de um composto, composição farmacêutica e uso de um composto'' |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06A | Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/05/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/01/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |